Meningitis epidemics in Africa: A brief overview

Vaccine

Volumn 25, Issue SUPPL. 1, 2007, Pages

  Teyssou, Rémy ^a   Muros Le Rouzic, Erwan ^b  

^a Louis Malardé Institute   (French Polynesia)

^b SANOFI PASTEUR   (France)

Author keywords

African Meningitis Belt; Epidemics; Meningitis

Indexed keywords

POLYSACCHARIDE VACCINE;

AFRICA; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL STRAIN; ENVIRONMENTAL FACTOR; EPIDEMIC; EPIDEMIC MENINGITIS; HEALTH SURVEY; HUMAN; NEISSERIA MENINGITIDIS; PANDEMIC; PERIODICITY; PRIORITY JOURNAL; SEASONAL VARIATION;

AFRICA; DISEASE OUTBREAKS; GEOGRAPHY; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES;

EID: 34547595514     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.04.032     Document Type: Article

References (33)

1. Caugant D.A. Population genetics and molecular epidemiology of Neisseria meningitidis. APMIS 106 5 (1998) 505-525
2. Maiden M.C., Bygraves J.A., Feil E., Morelli G., Russell J.E., Urwin R., et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA 95 6 (1998) 3140-3145
3. Lapeyssonnie L. La méningite cérébrospinale en Afrique. Bull World Health Organ 28 (1963) 1-114
4. Molesworth A.M., Cuevas L.E., Connor S.J., Morse A.P., and Thomson M.C. Environmental risk and meningitis epidemics in Africa. Emerg Infect Dis 9 10 (2003) 1287-1293
5. Wang J.F., Caugant D.A., Li X., Hu X., Poolman J.T., Crowe B.A., et al. Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China. Infect Immun 60 12 (1992) 5267-5282
6. Moore P.S., Reeves M.W., Schwartz B., Gellin B.G., and Broome C.V. Intercontinental spread of an epidemic group A Neisseria meningitidis strain. Lancet 2 8657 (1989) 260-263
7. Achtman M., Kusecek B., Morelli G., Eickmann K., Wang J.F., Crowe B., et al. A comparison of the variable antigens expressed by clone IV-1 and subgroup III of Neisseria meningitidis serogroup A. J Infect Dis 165 1 (1992) 53-68
8. Nicolas P., Décousset L., Riglet V., Castelli P., Stor R., and Blanchet G. Clonal Expansion of Sequence Type (ST-)5 and Emergence of ST-7 in Serogroup A Meningococci, Africa. Emerg Infect Dis 7 5 (2001) 849-854
9. Zhu P., Van Der E.A., Falush D., Brieske N., Morelli G., Linz B., et al. Fit genotypes and escape variants of subgroup III Neisseria meningitidis during three pandemics of epidemic meningitis. Proc Natl Acad Sci USA 98 9 (2001) 5234-5239
10. Moore P.S., Harrison L.H., Telzak E.E., Ajello G.W., and Broome C.V. Group A meningococcal carriage in travelers returning from Saudi Arabia. JAMA 260 18 (1988) 2686-2689
11. Guibourdenche M., Hoiby E.A., Riou J.Y., Varaine F., Joguet C., and Caugant D.A. Epidemics of serogroup A Neisseria meningitidis of subgroup III in Africa, 1989-94. Epidemiol Infect 116 2 (1996) 115-120
12. Achtman M., van der Ende A., Zhu P., Koroleva I.S., Kusecek B., Morelli G., et al. Molecular epidemiology of serogroup A meningitis in Moscow, 1969 to 1997. Emerg Infect Dis 7 3 (2001) 420-427
13. Chippaux J.P., Debois H., and Saliou P. A critical review of control strategies against meningococcal meningitis epidemics in sub-Saharan African countries. Infection 30 4 (2002) 216-224
14. Kwara A., Adegbola R.A., Corrah P.T., Weber M., Achtman M., Morelli G., et al. Meningitis caused by a serogroup W135 clone of the ET-37 complex of Neisseria meningitidis in West Africa. Trop Med Int Health 3 9 (1998) 742-746
15. Greenwood B.M., Smith A.W., Hassan-King M., Bijlmer H.A., Shenton F.C., Hughes A.S., et al. The efficacy of meningococcal polysaccharide vaccine in preventing group A meningococcal disease in The Gambia, West Africa. Trans R Soc Trop Med Hyg 80 6 (1986) 1006-1007
16. Djibo S., Nicolas P., Alonso J.M., Djibo A., Couret D., Riou J.Y., et al. Outbreaks of serogroup X meningococcal meningitis in Niger 1995-2000. Trop Med Int Health 8 12 (2003) 1118-1123
17. Mayer L.W., Reeves M.W., Al Hamdan N., Sacchi C.T., Taha M.K., Ajello G.W., et al. Outbreak of W135 Meningococcal Disease in 2000: Not Emergence of a New W135 Strain but Clonal Expansion within the Electophoretic Type-37 Complex. J Infect Dis 185 11 (2002) 1596-1605
18. Taha M.K., Parent D.C.I., Schlumberger M., Sanou I., Djibo S., de Chabalier F., et al. Neisseria meningitidis serogroups W135 and A were equally prevalent among meningitis cases occurring at the end of the 2001 epidemics in Burkina Faso and Niger. J Clin Microbiol 40 3 (2002) 1083-1084
19. Popovic T., Sacchi C.T., Reeves M.W., Whitney A.M., Mayer L.W., Noble C.A., et al. Neisseria meningitidis serogroup W135 isolates associated with the ET-37 complex. Emerg Infect Dis 6 4 (2000) 428-429
20. Anonymous. Meningococcal disease, serogroup W135, Burkina Faso. Preliminary report, 2002. Wkly Epidemiol Rec 77 18 (2002) 152-155
21. Wang J.F., Caugant D.A., Morelli G., Koumare B., and Achtman M. Antigenic and epidemiologic properties of the ET-37 complex of Neisseria meningitidis. J Infect Dis 167 6 (1993) 1320-1329
22. European Union Invasive Bacterial Infections Surveillance (EU-IBIS), Meningococci Network. Surveillance network for invasive Neisseria meningitidis in Europe-1999 & 2000. (available at http://www.euibis.org/documents/meningo19992000.pdf).
23. European Union Invasive Bacterial Infections Surveillance (EU-IBIS) Meningococci Network. Invasive Neisseria meningitidis in Europe-2001 (available at http://www.euibis.org/documents/EU_IBISmeningococci 2001reportFINALDRAFT.pdf).
24. Whalen C.M., Hockin J.C., Ryan A., and Ashton F. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992: Emergence of a virulent clone of Neisseria meningitidis. JAMA 273 5 (1995) 390-394
25. Pollard A.J., and Scheifele D. Meningococcal disease and vaccination in North America. J Paediatr Child Health 37 5 (2001) 20-27
26. Squires S.G., Deeks S., and Tsang R.S. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 1999, through 31 December, 2001. Can Commun Dis Rep 30 3 (2004) 17-28
27. Miller E., Salisbury D., and Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 20 Suppl 1 (2001) S58-S67
28. Salleras L., Dominguez A., Dominguez A., and Cardenosa N. Impact of mass vaccination with polysaccharide conjugate vaccine against serogroup C meningococcal disease in Spain. Vaccine 21 7-8 (2003) 725-728
29. Salleras L., Dominguez A., Dominguez A., and Cardenosa N. Dramatic decline of serogroup C meningococcal disease in Catalonia (Spain) after a mass vaccination campaign with meningococcal C conjugated vaccine. Vaccine 21 7-8 (2003) 729-733
30. Epidemiology of meningococcal C disease in Belgium one year after a mass immunization campaign. Abstracts of the 7th European monitoring group on Meningococci (EMGM), Lanzarote, Spain, September 24-27, 2003: 2003.
31. de Greeff S.C., de Melker H.E., Spanjaard L., van den H.S., and Dankert J. The first effect of the national vaccination campaign against meningococcal-C disease: a rapid and sharp decrease in the number of patients. Ned Tijdschr Geneeskd 147 23 (2003) 1132-1135
32. Anonymous. An advisory committee statement (ACS). National advisory committee on immunization (NACI). Supplementary statement on conjugate meningococcal vaccines. Can Commun Dis Rep 2003; 29(ACS-6):10-11.
33. Risk of epidemic meningitis in Africa: a cause for concern ; WER, N°10, 9 March 2007.